Westchester Capital Management (New York)’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Westchester Capital Management (New York)’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-16,116	Closed	-$2.12M	–	425
2020 Q4	$2.12M	Buy	+16,116	New	+$1.42M	0.07%	120

Westchester Capital Management (New York)'s EIDX Position: Q1 2021 in Review

Westchester Capital Management (New York) sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 16,116 shares — an estimated $2.12M sold.

Westchester Capital Management (New York) first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $2.12M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Westchester Capital Management (New York) reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Westchester Capital Management (New York) sold 16,116 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.12M.
Westchester Capital Management (New York) first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Westchester Capital Management (New York)'s Eidos Therapeutics, Inc. Common Stock position peaked at $2.12M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Westchester Capital Management (New York)'s 13F filing for Q1 2021, filed 17 May 2021.